Julia Lainster

The traditional landscape of pharmaceutical development often leaves academic institutions as mere suppliers of raw intellectual property rather than central players in the multi-billion-dollar drug manufacturing process. For years, the University of Alabama at Birmingham has functioned as a

The rapid convergence of advanced computational power and molecular biology has ushered in a transformative era where genetic sequences are no longer just edited but are architected from a digital blank slate. This shift represents a departure from traditional recombinant DNA techniques, moving

Expectant parents navigating the complex landscape of modern prenatal screening often encounter a frustrating wall of technical ambiguity known as variants of uncertain significance. While genome sequencing has drastically improved the ability to map the fetal genetic code, it frequently reveals

The rapid evolution of global pharmaceutical supply chains and medical technology necessitates a robust regulatory framework that balances safety with market speed. Under the leadership of Federal Commissioner Víctor Hugo Borja, the Federal Commission for Protection against Sanitary Risks, known as

The shift in the pharmaceutical landscape has reached a point where environmental stewardship is no longer an optional component of corporate social responsibility. For decades, the global pharmaceutical sector operated under the assumption that life-saving patient outcomes justified a heavy

The escalating prevalence of cognitive decline has prompted a shift in medical research toward understanding how metabolic health directly influences the long-term structural integrity of the human brain. Scientists are increasingly looking at glucagon-like peptide-1 receptor agonists, originally

Precision in oncology often hinges on the ability to distinguish microscopic malignant cells from healthy tissue, yet current imaging tools frequently fail during the most critical moments of a procedure. While surgeons increasingly rely on near-infrared fluorescence to navigate complex anatomical

Ivan Kairatov is a distinguished biopharma expert whose career has been defined by a deep commitment to research, development, and technological innovation. With an intricate understanding of the drug development lifecycle, he has witnessed firsthand how targeted therapies can transform patient

The pursuit of effective treatments for Duchenne muscular dystrophy has shifted focus toward managing cardiomyopathy, which currently stands as the most common cause of mortality for patients entering their second or third decade of life. Capricor Therapeutics recently faced significant headwinds

Recent breakthroughs in the field of molecular biology have unveiled a sophisticated biochemical mechanism that acts as a definitive binary toggle for malignant cellular proliferation, effectively governing the transition between dormant and aggressive tumor growth. For decades, oncologists